IV form of osteoporosis treatment approved


GlaxoSmithKline and Roche have received FDA approval for Boniva (ibandronate sodium) injection, the first intravenous treatment for postmenopausal osteoporosis. The drug provides an alternative for patients who cannot take an oral medication or are unable to remain upright for 30 to 60 minutes, a requirement when taking the tablet form of bisphosphonates. Ibandronate injection should be administered by a healthcare professional once every three months and will be available early this year.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.